Michael Cherny
Stock Analyst at Leerink Partners
(5.00)
# 7
Out of 4,842 analysts
110
Total ratings
54.43%
Success rate
139.28%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.15 | +160.28% | 2 | May 28, 2025 | |
| MCK McKesson | Maintains: Buy | $755 → $800 | $712.14 | +12.34% | 13 | May 9, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $18.32 | +25.55% | 11 | Apr 29, 2025 | |
| CAH Cardinal Health | Maintains: Buy | $150 → $155 | $153.80 | +0.78% | 11 | Apr 11, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $297.74 | +10.84% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $52.80 | -24.24% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $62.67 | +19.67% | 11 | Feb 13, 2025 | |
| PGNY Progyny | Maintains: Buy | $21 → $25 | $21.39 | +16.88% | 10 | Feb 11, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $52.11 | +72.71% | 2 | Feb 7, 2025 | |
| ALGN Align Technology | Upgrades: Outperform | $235 → $280 | $182.66 | +53.29% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 → $174 | $171.92 | +1.21% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $73.25 | +14.68% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $139.11 | +78.28% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $130.76 | +95.01% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.40 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $290.25 | -5.25% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $23 → $22 | $11.19 | +96.60% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $246.45 | +5.50% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $23 | $22.93 | -1.88% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $3.78 | +111.92% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $11.33 | +67.70% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.12 | +138.93% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $5.86 | +795.90% | 2 | Jan 5, 2022 |
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.15
Upside: +160.28%
McKesson
May 9, 2025
Maintains: Buy
Price Target: $755 → $800
Current: $712.14
Upside: +12.34%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $18.32
Upside: +25.55%
Cardinal Health
Apr 11, 2025
Maintains: Buy
Price Target: $150 → $155
Current: $153.80
Upside: +0.78%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $297.74
Upside: +10.84%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $52.80
Upside: -24.24%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $62.67
Upside: +19.67%
Progyny
Feb 11, 2025
Maintains: Buy
Price Target: $21 → $25
Current: $21.39
Upside: +16.88%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $52.11
Upside: +72.71%
Align Technology
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $182.66
Upside: +53.29%
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $171.92
Upside: +1.21%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $73.25
Upside: +14.68%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $139.11
Upside: +78.28%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $130.76
Upside: +95.01%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $16.40
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $290.25
Upside: -5.25%
Mar 18, 2024
Maintains: Market Perform
Price Target: $23 → $22
Current: $11.19
Upside: +96.60%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $246.45
Upside: +5.50%
Feb 26, 2024
Initiates: Market Perform
Price Target: $23
Current: $22.93
Upside: -1.88%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $3.78
Upside: +111.92%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $11.33
Upside: +67.70%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.12
Upside: +138.93%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $5.86
Upside: +795.90%